Abionic

Executive Summary

Abionic is a Swiss diagnostics company that has developed the abioSCOPE®, a platform leveraging nanofluidics to deliver rapid, lab-quality results from a single drop of blood. Its flagship assay, PSP (Pancreatic Stone Protein), measures a biomarker that indicates a patient's risk of developing sepsis. The test is designed for emergency and critical care settings, where early detection of sepsis is critical for improving patient outcomes. By providing actionable results within minutes, abioSCOPE enables healthcare professionals to activate sepsis bundles earlier, potentially reducing mortality and healthcare costs. The company has established a strong foothold in Europe and is seeking to expand its commercial reach. Abionic's technology addresses a clear unmet need in sepsis management, where time-to-diagnosis is a key determinant of success. With its innovative approach and focus on high-acuity settings, Abionic is well-positioned to capture market share in the global diagnostics market, though it faces competition from established players and new entrants. The company's future growth hinges on regulatory approvals in key markets like the US and strategic partnerships to scale commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for PSP Assay55% success
• H2 2026Partnership with Major US Hospital Network40% success
• Q3 2026Publication of Key Clinical Study Results70% success